Paraoxonase Inhibition by Propranolol

authors:

avatar Alireza Jahangiri 1 , avatar Masoud Mahmoudian 2 , avatar Hassan Jalalizadeh 1 , avatar Abbas Shafiee 1 , *

Department of Medicinal Chemistry and Pharmaceutical Sciences Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
Department of Pharmacology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran

how to cite: Jahangiri A, Mahmoudian M, Jalalizadeh H, Shafiee A. Paraoxonase Inhibition by Propranolol. Iran J Pharm Res. 2004;3(3):e128199. https://doi.org/10.22037/ijpr.2010.593.

Abstract

There are many evidences that human serum paraoxonase activity modifies plasma lipid profile and paraoxonase has an antiatherogenic property. Non-selective beta-blockers affect plasma lipid profile too, but they have atherogenic property when patients take these drugs in long term. In this study the effect of propranolol, a non-selective beta-blocker, on paraoxonase activity was investigated. Lineweaver-Burk and secondary plots were drawn and showed that propranolol is a mixed non-competitive inhibitor of paraoxonase.